Implantable cardioverter defibrillators in patients with orthotopic heart transplant: A multicenter case series.
advanced heart failure
appropriate therapy
heart transplantation
implantable cardioverter defibrillator
sudden cardiac death
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
11
05
2022
received:
21
03
2022
accepted:
19
05
2022
pubmed:
8
6
2022
medline:
24
8
2022
entrez:
7
6
2022
Statut:
ppublish
Résumé
Sudden cardiac death (SCD) is common after orthotopic heart transplant (OHT). No clear guidelines for implantable cardioverter defibrillator (ICD) implantation in OHT patients at high risk for SCD currently exist. To assess the safety, efficacy, and benefit of ICDs and resynchronization therapy post-OHT. We also provide a systematic review of previous reports. A retrospective multicenter cohort study within the United States. Patients with ICD post-OHT between 2000 and 2020 were identified. We analyzed 16 patients from 4 centers. The mean standard-deviation (SD) age was 43 (18) years at OHT and 51 (20) years at ICD implantation. The mean (SD) duration from OHT to ICD implantation was 9 (5) years. The mean (SD) left ventricular ejection fraction (LVEF) was 35% (17%). There were 2 (13%) postprocedural complications: 1 hematoma and 1 death. Mean (SD) follow-up was 24 (23) months. Survival rate was 63% (10/16) at 1 year and 56% (9/16) at 2 years, with 6/7 of those who died having LVEF < 35% at the time of the ICD implantation. Patients were more likely to receive appropriate therapy if their ICD was implanted for secondary (5/8) rather than primary (0/8) prevention (p = .007). Of those who did, 4 patients survived to 30 days post-ICD therapy. Severe CAV was not associated with the rate of appropriate therapy. Beneficial outcomes were observed when ICDs were implanted for secondary prevention only, and in patients with higher baseline LVEF. We also observed benefits with resynchronization therapy.
Sections du résumé
BACKGROUND
Sudden cardiac death (SCD) is common after orthotopic heart transplant (OHT). No clear guidelines for implantable cardioverter defibrillator (ICD) implantation in OHT patients at high risk for SCD currently exist.
OBJECTIVES
To assess the safety, efficacy, and benefit of ICDs and resynchronization therapy post-OHT. We also provide a systematic review of previous reports.
METHODS
A retrospective multicenter cohort study within the United States. Patients with ICD post-OHT between 2000 and 2020 were identified.
RESULTS
We analyzed 16 patients from 4 centers. The mean standard-deviation (SD) age was 43 (18) years at OHT and 51 (20) years at ICD implantation. The mean (SD) duration from OHT to ICD implantation was 9 (5) years. The mean (SD) left ventricular ejection fraction (LVEF) was 35% (17%). There were 2 (13%) postprocedural complications: 1 hematoma and 1 death. Mean (SD) follow-up was 24 (23) months. Survival rate was 63% (10/16) at 1 year and 56% (9/16) at 2 years, with 6/7 of those who died having LVEF < 35% at the time of the ICD implantation. Patients were more likely to receive appropriate therapy if their ICD was implanted for secondary (5/8) rather than primary (0/8) prevention (p = .007). Of those who did, 4 patients survived to 30 days post-ICD therapy. Severe CAV was not associated with the rate of appropriate therapy.
CONCLUSIONS
Beneficial outcomes were observed when ICDs were implanted for secondary prevention only, and in patients with higher baseline LVEF. We also observed benefits with resynchronization therapy.
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1813-1822Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Vakil K, Taimeh Z, Sharma A, et al. Incidence, predictors, and temporal trends of sudden cardiac death after heart transplantation. Heart Rhythm. 2014;11:1684-1690.
Vaseghi M, Lellouche N, Ritter H, et al. Mode and mechanisms of death after orthotopic heart transplantation. Heart Rhythm. 2009;6:503-509.
Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72:1677-1749.
McDowell DL, Hauptman PJ. Implantable defibrillators and cardiac resynchronization therapy in heart transplant recipients: results of a national survey. J Heart Lung Transplant. 2009;28:847-850.
Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant. 2010;29:717-727.
Khaira KB, Singh R, Simon JW, Shirazi JT, Dandamudi G. Use of His-Bundle pacing for the treatment of left bundle branch Block-Induced cardiomyopathy following orthotopic heart transplantation: A case report. J Card Failure. 2019;25:S55-S56.
Neylon A, Canniffe C, Parlon B, Mahon N, O'Neill JO. Implantable cardioverter-defibrillators in a heart transplant population: a single-center experience. J Heart Lung Transplant. 2016;35:682-684.
Tsai VW, Cooper J, Garan H, et al. The efficacy of implantable cardioverter-defibrillators in heart transplant recipients: results from a multicenter registry. Circ Heart Fail. 2009;2:197-201.
Rubin G, DeFilippis EM, Farr MA, Topkara VK, Yarmohammadi H. Implantable Cardioverter-defibrillator use after heart transplantation. JACC: Clinical Electrophysiology. 2021;7:1314-1315.
Ptaszek LM, Wang PJ, Hunt SA, Valantine H, Perlroth M, Al-Ahmad A. Use of the implantable cardioverter-defibrillator in long-term survivors of orthotopic heart transplantation. Heart Rhythm. 2005;2:931-933.
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810-1852.
Alba AC, Fan CS, Manlhiot C, Dipchand AI, Stehlik J, Ross HJ. The evolving risk of sudden cardiac death after heart transplant. An analysis of the ISHLT thoracic transplant registry. Clin Transplant. 2019;33:e13490.
Alba AC, Foroutan F, Ng Fat Hing NKV, Fan CS, Manlhiot C, Ross HJ. Incidence and predictors of sudden cardiac death after heart transplantation: a systematic review and meta-analysis. Clin Transplant. 2018;32:e13206.
Montpetit M, 1 MS, Muller E, et al. Sudden cardiac death om heart transplant patients: is there a role for defibrillators? J Heart Lung Transplant. 2007;00:S182.
Cogert GA, Shivkumar K, Patel JK, et al. Implantable cardioverter defibrillators in heart transplant patients at risk for sudden death: shocking news? J Heart Lung Transplant. 2003;00:S178-S179.
Marzoa-Rivas R, Perez-Alvarez L, Paniagua-Martin MJ, et al. Sudden cardiac death of two heart transplant patients with correctly functioning implantable cardioverter defibrillators. J Heart Lung Transplant. 2009;28:412-414.
DeFilippis ARG EM, Givens RC, Truby LK, et al. Implantable cardioverter-defibrillators in heart transplant recipients with allograft failure. J Heart Lung Transplant. 2019;38:S286-S287.
DeFilippis EM, Rubin G, Farr MA, et al. Cardiac implantable electronic devices following heart transplantation. JACC: Clin Electrophysiol. 2020;6:1028-1042.
Vakil K, Duval S, Cogswell R, et al. Impact of implantable cardioverter-defibrillators on waitlist mortality among patients awaiting heart transplantation: an UNOS/OPTN analysis. JACC Clin Electrophysiol. 2017;3:33-40.
Meyer DM, Rogers JG, Edwards LB, et al. The future direction of the adult heart allocation system in the United States. Am J Transplant. 2015;15:44-54.
Ranasinghe I, Parzynski CS, Freeman JV, et al. Long-term risk for device-related complications and reoperations after implantable cardioverter-defibrillator implantation: an observational cohort study. Ann Intern Med. 2016;165:20-29.
Kaushal M, Leff J, Gross J, Jakobleff WA, Jr., Forest S, Leyvi G. Reporting the first subcutaneous ICD placed in the immediate postorthotopic heart transplant period for acute cellular Rejection-Associated cardiac arrest and investigating the role of secondary prevention ICDs in this population. J Cardiothorac Vasc Anesth. 2017;31:1784-1788.
Vinther M, Risum N, Svendsen JH, Møgelvang R, Philbert BT. A randomized trial of His pacing versus biventricular pacing in symptomatic heart failure patients with left bundle branch block (His-Alternative). JACC: Clin Electrophysiol. 2021;7:1422-1432.
Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. multicenter unsustained tachycardia trial investigators. N Engl J Med. 1999;341:1882-1890.
Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237.